The Global Breakthrough of TROP2 ADC for Lung Cancer: A Chinese Innovative Drug Reshaping the Treatment Landscape for EGFR-Mutated Lung Cancer
Compiled by: Oncology NewsSource: Oncology News In the field of lung cancer treatment, patients with EGFR-mutated non-small cell lung cancer (NSCLC) have long faced a “treatment desert” after developing resistance to TKI therapy, with traditional chemotherapy offering limited efficacy and significant side effects. The Chinese innovative drug, sacituzumab tirapazamine, developed by Professor Zhang Li’s team, … Read more